文献速递细菌感染、耐药与抗菌药物医院感染防控

感染病专家融入基层抗菌药物管理:多中心整群随机盲法结局评估试验

Integrating infectious disease experts into primary care antibiotic stewardship: a multicentre, cluster-randomized, outcome-assessor-blinded trial.
PubMed 文献 · Clin Microbiol Infect · 2026-10-08

在西班牙加泰罗尼亚6个初级保健中心开展多中心整群随机试验,比较标准抗菌药物管理(AMS)与融入感染病(ID)专家支持的高级AMS对上下呼吸道和尿路感染抗菌药物消耗及处方质量的影响。结果显示高级AMS未显著降低总抗菌药物消耗,但减少了不必要和不恰当处方,且未增加30天再就诊或住院。

要点

  • 高级AMS未显著降低总抗菌药物消耗(DID组间差异无统计学意义)。
  • 高级AMS使不必要处方比例从28.3%降至21.2%(OR 0.68)。
  • 高级AMS使不恰当处方比例从52.9%降至38.8%(OR 0.54)。

核心结论

  • 融入感染病专家未显著降低初级保健总抗菌药物消耗,但改善了处方质量且未影响患者安全。

研究设计与样本

  • 多中心整群随机、结局评估者盲法试验,纳入西班牙加泰罗尼亚6个初级保健中心,所有中心实施标准AMS,其中3个中心随机分配接受感染病专家电话热线和双周会议支持的高级AMS。
  • 研究对象为年龄超过14岁的上呼吸道感染或尿路感染患者,通过时点患病率调查评估不必要和不恰当处方及30天再就诊或住院。

主要发现

  • 2021年10月至2023年3月,总体抗菌药物消耗从7.08(SD 1.29)DID增至7.79(SD 1.65)DID(平均差+0.71,95%CI 0.13-1.28)。
  • 高级AMS组消耗从7.16(SD 1.33)DID增至7.56(SD 1.44)DID(+0.40,95%CI -0.40至1.20),标准AMS组从7.00(SD 1.29)DID增至8.01(SD 1.82)DID(+1.01,95%CI 0.15-1.88)。
  • Poisson回归显示干预期间每月DID增加4%(IRR 1.04,95%CI 1.01-1.06),组间无差异(IRR 0.95,95%CI 0.19-4.74)。
  • 上呼吸道感染/尿路感染 episodes 中,25.0%(347/1389)处方不必要,50.3%(524/1042)有指征治疗不恰当。
  • 干预结束时,高级AMS较标准AMS减少不必要处方(21.2%(100/471)vs. 28.3%(145/512)%;OR 0.68,95%CI 0.51-0.91)和不恰当处方(38.8%(144/371)vs. 52.9%(194/367)%;OR 0.54,95%CI 0.36-0.81);再就诊或住院无显著差异。

临床怎么用

  • 在初级保健AMS框架中嵌入感染病专家支持可改善上下呼吸道和尿路感染的处方质量,且不增加再就诊或住院风险。
  • 卫生政策制定者可考虑将感染病专业知识整合入初级保健AMS体系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to assess the impact of integrating infectious disease (ID) experts into primary care antimicrobial stewardship (AMS) programmes on antibiotic consumption and prescribing adequacy for upper respiratory tract infections (URTIs) and urinary tract infections (UTIs). METHODS: A multicentre, cluster-randomized trial across six primary care centres in Catalonia, Spain. All centres implemented a standard AMS programme, with three centres randomly assigned to an advanced AMS (receiving ID expert support via a telephone helpline and biweekly meetings). The primary endpoint was total antibiotic consumption (defined daily doses per 1000 inhabitants per day (DID)). Secondary endpoints included unnecessary and inadequate prescriptions and 30-day reconsultations or hospitalizations, evaluated through point-prevalence surveys in patients aged over 14 years with URTI or UTI. RESULTS: Between October 2021 and March 2023, overall antibiotic consumption increased from 7.08 (SD 1.29) to 7.79 (SD 1.65) DID (mean difference +0.71 (95% CI, 0.13-1.28)). This rise was lower under advanced AMS, from 7.16 (SD 1.33) to 7.56 (SD 1.44) DID (+0.40 (95% CI, -0.40 to 1.20)) than standard AMS, from 7.00 (SD 1.29) to 8.01 (SD 1.82) DID (+1.01 (95% CI, 0.15-1.88)). During the intervention, Poisson regression showed a 4% monthly DID increase (incidence rate ratios 1.04 (95% CI, 1.01-1.06)), without intergroup differences (incidence rate ratios 0.95 (95% CI, 0.19-4.74)). Across URTI/UTI episodes, 25.0 (347/1389)% of prescriptions were unnecessary and 50.3 (524/1042)% of indicated treatments were inadequate. By end of intervention, advanced AMS reduced unnecessary (21.2 (100/471)% vs. 28.3 (145/512)%; OR 0.68 (95% CI, 0.51-0.91)) and inadequate prescriptions (38.8 (144/371)% vs. 52.9 (194/367)%; OR 0.54 (95% CI, 0.36-0.81)) compared with standard AMS. Reconsultations or hospitalizations showed no significant differences. CONCLUSIONS: Integrating ID experts into primary care AMS did not demonstrate a statistically significant reduction in total antibiotic use. However, the data suggest a positive impact on prescribing quality without compromising patient safety. Health policymakers should consider embedding ID expertise within primary care AMS frameworks.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ronda M, Padullés A, Carratalà J, et al. Integrating infectious disease experts into primary care antibiotic stewardship: a multicentre, cluster-randomized, outcome-assessor-blinded trial. Clin Microbiol Infect. 2026. PMID: 42849833. doi:10.1016/j.cmi.2026.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。